Vanda Pharmaceuticals, Inc. (VNDA)

[surf1944]

1:30AM Vanda Pharma receives negative opinion from CHMP on Fanaptum for the treatment of schizophrenia (VNDA) 3.22 : Co announces that the European Medicines Agency's Committee for Medicinal Product for Human Use has issued a negative opinion recommending against approval of Fanaptum for the treatment of schizophrenia in adult patients in the European Union. The CHMP was of the opinion that the benefits of Fanaptum did not outweigh its risks and recommended against marketing authorization at this point in time. Vanda intends to appeal this opinion and request a re-examination of the decision by the CHMP.